MAC Clinical Research and Initiator Pharma Complete Dosing in Phase 2a Vulvodynia Study

Share article:

Facebook
WhatsApp
Twitter
LinkedIn
MAC and Initiator Pharma Complete Dosing in Phase 2a Vulvodynia Study

Recruitment and dosing have now been completed in Initiator Pharma’s Phase 2a clinical proof-of-concept study of pudafensine, an investigational treatment for women with vulvodynia.

As Initiator Pharma’s full-service CRO partner, MAC has supported the delivery of the study, which involved 24 women diagnosed with vulvodynia.

The randomised, placebo-controlled study uses a four-way crossover design, with participants receiving single oral doses of pudafensine and placebo across different treatment periods, separated by washout intervals. The study aims to evaluate the pain-relieving effects and safety of pudafensine.

Vulvodynia is a chronic pain condition affecting the vulva, often causing discomfort during everyday activities such as sitting, walking and sexual intercourse. Despite its impact on quality of life, treatment options remain limited, with no medications currently specifically approved for the condition.

MAC first announced its partnership for the vulvodynia trial with Initiator Pharma in November 2025. The study subsequently progressed through participant recruitment, with dosing completed at the end of October 2026.

The completion of dosing marks an important milestone in the collaboration, bringing the study closer to providing its first clinical proof-of-concept data in vulvodynia.

The results are expected in February 2027 and will provide further insight into pudafensine’s potential as a treatment for this condition.

You can read the full announcement from Initiator Pharma here.

Share article:

Facebook
WhatsApp
Twitter
LinkedIn